---
title: "Immunome | 8-K: FY2026 Q2 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295574251.md"
datetime: "2026-08-11T20:12:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295574251.md)
  - [en](https://longbridge.com/en/news/295574251.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295574251.md)
generator: "portal-rs"
---

# Immunome | 8-K: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.65, missing the estimate of USD -0.5175.

EBIT: As of FY2026 Q2, the actual value is USD -73.13 M.

### Financial Highlights (Three Months Ended June 30, 2026 vs. 2025)

#### Cash and Liquidity

-   As of June 30, 2026, cash, cash equivalents, and marketable securities totaled $520.0 million.

#### Revenue

-   Collaboration revenue for the three months ended June 30, 2026, was $0, compared to $4.0 million for the same period in 2025.

#### Operating Expenses

-   Research and development expenses were $59.9 million for the three months ended June 30, 2026, an increase from $40.5 million in the prior year period.
    -   This included stock-based compensation expense of $4.2 million in Q2 2026, up from $2.2 million in Q2 2025.
-   General and administrative expenses were $18.3 million for the three months ended June 30, 2026, compared to $10.0 million for the same period in 2025.
    -   This included stock-based compensation expense of $4.6 million in Q2 2026, up from $3.1 million in Q2 2025.
-   Total operating expenses for the three months ended June 30, 2026, were $78.1 million, an increase from $50.5 million in the prior year period.

#### Operating Loss and Net Loss

-   Loss from operations for the three months ended June 30, 2026, was - $78.1 million, compared to - $46.5 million for the same period in 2025.
-   Interest income for the three months ended June 30, 2026, was $5.0 million, up from $3.1 million in the prior year period.
-   Net loss for the three months ended June 30, 2026, was - $73.1 million, compared to - $43.4 million for the same period in 2025.
-   Net loss per share, basic and diluted, was - $0.65 for Q2 2026, compared to - $0.50 for Q2 2025.
-   Total share-based compensation expense for the quarter was $8.8 million in 2026, versus $5.3 million in 2025.

#### Comprehensive Loss

-   Comprehensive loss for the three months ended June 30, 2026, was - $73.5 million, compared to - $43.4 million for the same period in 2025.
-   Unrealized loss on marketable securities was - $0.3 million in Q2 2026, compared to - $0.021 million in Q2 2025.

### Operational Metrics and Pipeline Highlights

#### Varegacestat

-   The U.S. FDA accepted Immunome, Inc.’s New Drug Application (NDA) for varegacestat, setting a PDUFA target action date of April 28, 2027.
-   Detailed efficacy and safety results from the Phase 3 RINGSIDE trial demonstrated an 84% reduction in the risk of disease progression or death versus placebo (p<0.0001) and met all key secondary endpoints, including a confirmed objective response rate of 56% versus 9% with placebo (p<0.0001).
-   Varegacestat also showed statistically significant improvement in worst pain intensity at week 12, with a clinically significant difference observed as early as week 4.

#### IM-1021

-   The Phase 1 clinical trial is ongoing, with objective responses observed in participants with B-cell lymphoma.

#### IM-1617

-   The first patient was dosed in June 2026 in the Phase 1, first-in-human trial for advanced solid tumors.

#### IM-3050

-   The first patient was dosed in July 2026 in the Phase 1, first-in-human trial for FAP-expressing advanced solid tumors.

#### Preclinical ADC Pipeline

-   Immunome, Inc. expects to submit Investigational New Drug (IND) applications for IM-1340 and IM-1335 in mid- and late 2026, respectively.

### Outlook / Guidance

Immunome, Inc. expects its current cash position to fund operations into 2028. The company plans to submit a Marketing Authorization Application for varegacestat to the European Medicines Agency by the end of 2026. Additionally, Immunome, Inc. anticipates presenting initial lymphoma data for IM-1021 in 2026 and submitting INDs for IM-1340 and IM-1335 in mid- and late 2026, respectively.

### Related Stocks

- [IMNM.US](https://longbridge.com/en/quote/IMNM.US.md)

## Related News & Research

- [Immunome (IMNM) Starts IM 3050 Trial As Valuation Questions Come Into View](https://longbridge.com/en/news/295500222.md)
- [Immunome director Isaac Barchas reports disposal of common shares worth $2.18 million](https://longbridge.com/en/news/295714134.md)
- [WhiteFiber amends 8-K to file real estate purchase and sale agreement as exhibit](https://longbridge.com/en/news/297088090.md)
- [Northann amends 8-K to file former auditor LAO Professionals’ letter on resignation](https://longbridge.com/en/news/296825824.md)
- [HRL: Raised fiscal 2026 adjusted EPS guidance after strong adjusted earnings and cash flow](https://longbridge.com/en/news/297163071.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**